Connection
David Camidge to Head and Neck Neoplasms
This is a "connection" page, showing publications David Camidge has written about Head and Neck Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.128 |
|
|
|
-
Do KT, Chow LQM, Reckamp K, Sanborn RE, Burris H, Robert F, Camidge DR, Steuer CE, Strickler JH, Weise A, Specht JM, Gutierrez M, Haughney P, Hengel S, Derleth CL, Yap TA. First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. Oncologist. 2021 11; 26(11):925-e1918.
Score: 0.128